Does the media favor GRCE or DERM?

In the previous week, Journey Medical had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 2 mentions for Journey Medical and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Journey Medical's score of 0.42 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Journey Medical 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GRCE or SLGL?

In the previous week, Sol-Gel Technologies had 5 more articles in the media than Grace Therapeutics. MarketBeat recorded 6 mentions for Sol-Gel Technologies and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Sol-Gel Technologies' score of 0.81 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sol-Gel Technologies 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, GRCE or NERV?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A

Is GRCE or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -36.11% -34.39% Minerva Neurosciences N/A N/A -31.72%

Does the media favor GRCE or NERV?

In the previous week, Minerva Neurosciences had 2 more articles in the media than Grace Therapeutics. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Minerva Neurosciences' score of 0.82 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MENS or GRCE?

Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 191.26%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, MENS or GRCE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A

Is MENS or GRCE more profitable?

Jyong Biotech's return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Grace Therapeutics N/A -36.11% -34.39%

Does the media refer more to LFCR or GRCE?

In the previous week, Lifecore Biomedical had 16 more articles in the media than Grace Therapeutics. MarketBeat recorded 17 mentions for Lifecore Biomedical and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Lifecore Biomedical's score of -0.04 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Grace Therapeutics (GRCE) Competitors

$2.06 -0.01 (-0.48%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.00 (+0.24%)

As of 10/5/2026 07:30 PM Eastern

Compare

GRCE vs. DERM, SLGL, NERV, MENS, and LFCR

Should you buy Grace Therapeutics stock or one of its competitors? Grace Therapeutics's main competitors and comparable companies include Journey Medical (DERM), Sol-Gel Technologies (SLGL), Minerva Neurosciences (NERV), Jyong Biotech (MENS), and Lifecore Biomedical (LFCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Grace Therapeutics compare to Journey Medical?

Grace Therapeutics (NASDAQ:GRCE) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

In the previous week, Journey Medical had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 2 mentions for Journey Medical and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Journey Medical's score of 0.42 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Journey Medical	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grace Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 191.26%. Journey Medical has a consensus target price of $14.00, suggesting a potential upside of 109.27%. Given Grace Therapeutics' higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Grace Therapeutics has higher earnings, but lower revenue than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Journey Medical	$68.18M	2.77	-$11.43M	-$0.22	N/A

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Grace Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Journey Medical	-8.95%	-20.23%	-6.60%

Grace Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Summary

Journey Medical beats Grace Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Grace Therapeutics compare to Sol-Gel Technologies?

Grace Therapeutics (NASDAQ:GRCE) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

In the previous week, Sol-Gel Technologies had 5 more articles in the media than Grace Therapeutics. MarketBeat recorded 6 mentions for Sol-Gel Technologies and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Sol-Gel Technologies' score of 0.81 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 191.26%. Sol-Gel Technologies has a consensus price target of $197.50, indicating a potential upside of 150.16%. Given Grace Therapeutics' higher probable upside, equities analysts plainly believe Grace Therapeutics is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 10.8% of Grace Therapeutics shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sol-Gel Technologies has higher revenue and earnings than Grace Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Sol-Gel Technologies	$1.80M	123.59	-$6.13M	-$5.64	N/A

Grace Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Grace Therapeutics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Grace Therapeutics' return on equity of -36.11% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Summary

Sol-Gel Technologies beats Grace Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Grace Therapeutics compare to Minerva Neurosciences?

Grace Therapeutics (NASDAQ:GRCE) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

Minerva Neurosciences' return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Minerva Neurosciences	N/A	N/A	-31.72%

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Minerva Neurosciences had 2 more articles in the media than Grace Therapeutics. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Minerva Neurosciences' score of 0.82 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 191.26%. Minerva Neurosciences has a consensus price target of $10.33, indicating a potential upside of 211.24%. Given Minerva Neurosciences' higher possible upside, analysts clearly believe Minerva Neurosciences is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Grace Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market.

Summary

Grace Therapeutics and Minerva Neurosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Grace Therapeutics compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Jyong Biotech's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Grace Therapeutics	N/A	-36.11%	-34.39%

In the previous week, Grace Therapeutics had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 1 mentions for Grace Therapeutics and 0 mentions for Jyong Biotech. Grace Therapeutics' average media sentiment score of 0.91 beat Jyong Biotech's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Jyong Biotech	Neutral
Grace Therapeutics	Positive

6.1% of Grace Therapeutics shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Jyong Biotech has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 191.26%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Grace Therapeutics beats Jyong Biotech on 7 of the 11 factors compared between the two stocks.

How does Grace Therapeutics compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Grace Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.91	-$40.50M	-$1.07	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Grace Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Grace Therapeutics	N/A	-36.11%	-34.39%

Lifecore Biomedical has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

In the previous week, Lifecore Biomedical had 16 more articles in the media than Grace Therapeutics. MarketBeat recorded 17 mentions for Lifecore Biomedical and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Lifecore Biomedical's score of -0.04 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grace Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical presently has a consensus price target of $6.50, indicating a potential downside of 0.31%. Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 191.26%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Lifecore Biomedical beats Grace Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCE vs. The Competition

Export

Metric	Grace Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$43.54M	$12.24B	$7.14B	$13.26B
Dividend Yield	N/A	2.65%	2.54%	17.37%
P/E Ratio	-1.75	799.72	274.34	26.20
Price / Sales	N/A	790.22	577.41	78.74
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	0.52	10.67	11.20	6.40
Net Income	-$7.79M	$2.83B	$3.49B	$381.07M
7 Day Performance	-2.37%	-2.04%	-1.37%	-0.30%
1 Month Performance	-1.90%	-6.58%	-6.02%	-4.53%
1 Year Performance	-31.79%	-4.72%	7.24%	1.62%

Grace Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCE Grace Therapeutics	2.0046 of 5 stars	$2.06 -0.5%	$6.00 +191.3%	-32.0%	$43.54M	N/A	N/A	5	Analyst Downgrade
DERM Journey Medical	1.7564 of 5 stars	$6.14 -2.8%	$14.00 +128.0%	-8.7%	$178.38M	$61.86M	N/A	58
SLGL Sol-Gel Technologies	3.2608 of 5 stars	$66.85 +10.1%	$197.50 +195.4%	+126.9%	$170.67M	$19.39M	N/A	28
NERV Minerva Neurosciences	1.8161 of 5 stars	$3.40 -1.4%	$10.33 +203.9%	+56.7%	$164.73M	N/A	N/A	7	Positive News
MENS Jyong Biotech	N/A	$2.03 -5.6%	N/A	-95.7%	$163.46M	N/A	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCE) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grace Therapeutics (GRCE) Competitors

GRCE vs. DERM, SLGL, NERV, MENS, and LFCR

How does Grace Therapeutics compare to Journey Medical?

Summary

How does Grace Therapeutics compare to Sol-Gel Technologies?

Summary

How does Grace Therapeutics compare to Minerva Neurosciences?

Summary

How does Grace Therapeutics compare to Jyong Biotech?

Summary

How does Grace Therapeutics compare to Lifecore Biomedical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grace Therapeutics (GRCE) Competitors

GRCE vs. DERM, SLGL, NERV, MENS, and LFCR

How does Grace Therapeutics compare to Journey Medical?

Does the media favor GRCE or DERM?

Do analysts recommend GRCE or DERM?

Which has better valuation and earnings, GRCE or DERM?

Do institutionals and insiders hold more shares of GRCE or DERM?

Is GRCE or DERM more profitable?

Which has more volatility & risk, GRCE or DERM?

Summary

How does Grace Therapeutics compare to Sol-Gel Technologies?

Does the media favor GRCE or SLGL?

Do analysts recommend GRCE or SLGL?

Do insiders & institutionals have more ownership in GRCE or SLGL?

Which has higher valuation and earnings, GRCE or SLGL?

Which has more volatility and risk, GRCE or SLGL?

Is GRCE or SLGL more profitable?

Summary

How does Grace Therapeutics compare to Minerva Neurosciences?

Which has stronger valuation and earnings, GRCE or NERV?

Is GRCE or NERV more profitable?

Do institutionals & insiders have more ownership in GRCE or NERV?

Does the media favor GRCE or NERV?

Do analysts rate GRCE or NERV?

Which has more volatility and risk, GRCE or NERV?

Summary

How does Grace Therapeutics compare to Jyong Biotech?

Which has higher valuation & earnings, MENS or GRCE?

Is MENS or GRCE more profitable?

Does the media refer more to MENS or GRCE?

Do institutionals and insiders believe in MENS or GRCE?

Which has more volatility and risk, MENS or GRCE?

Do analysts recommend MENS or GRCE?

Summary

How does Grace Therapeutics compare to Lifecore Biomedical?

Which has better valuation and earnings, LFCR or GRCE?

Is LFCR or GRCE more profitable?

Which has more risk and volatility, LFCR or GRCE?

Does the media refer more to LFCR or GRCE?

Do analysts prefer LFCR or GRCE?

Do insiders & institutionals believe in LFCR or GRCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools